Urokinase-type plasminogen activator and its receptor synergize to promote pathogenic proteolysis

EMBO Journal

Volumn 19, Issue 17, 2000, Pages 4817-4826

  Zhou, Hong Ming ^a   Nichols, Anthony ^a,b   Meda, Paolo ^a   Vassalli, Jean Dominique ^a  

^a UNIVERSITY OF GENEVA   (Switzerland)

^b SERONO PHARMACEUTICAL RES INSTITUTE   (Switzerland)

Author keywords

Alopecia; Epidermal thickening; Hair follicle involution; Skin blistering; uPA

Indexed keywords

UROKINASE RECEPTOR;

ALOPECIA; ANIMAL CELL; ARTICLE; BINDING AFFINITY; CATALYSIS; CATALYST; CELL INTERACTION; EXTRACELLULAR MATRIX; GENETIC REGULATION; MOUSE; NONHUMAN; PATHOGENICITY; PRIORITY JOURNAL; PROTEIN DEGRADATION; RECEPTOR AFFINITY; RECEPTOR BINDING; TISSUE SPECIFICITY;

EID: 0034282829     PISSN: 02614189     EISSN: None     Source Type: Journal    
DOI: 10.1093/emboj/19.17.4817     Document Type: Article

References (61)

1. Tumor dormancy induced by downregulation of urokinase receptor in human carcinoma involves integrin and MAPK signaling
2. Inhibition of mammary tumor cell adhesion, migration and invasion by the selective synthetic urokinase inhibitor B428
3. Interaction of heparin with plasminogen activators and plasminogen: Effects on the activation of plasminogen
4. Soluble fibrin preparations inhibit the reaction of plasmin with α2-macroglobulin. Comparison with α2-antiplasmin and leupeptin
5. The receptor-binding sequence of urokinase. A biological function for the growth-factor module of proteases
6. uPA, uPAR, PAI-1: Key intersection of proteolytic, adhesive and chemotactic highways?
7. The receptor for urokinase-type plasminogen activator is not essential for mouse development or fertility
8. Plasminogen binding sites in normal human skin
9. Physiological consequences of loss of plasminogen activator gene function in mice
10. Natural inhibitors of fibrinolysis
11. Prevention of metastasis by inhibition of the urokinase receptor
12. Cancer invasion and tissue remodeling - Cooperation of protease systems and cell types
13. The urokinase-type-plasminogen-activator receptor (CD87) is a pleiotropic molecule
14. Urokinase plasminogen activator: A prognostic marker in multiple types of cancer
15. Plasminogen activation by receptor-bound urokinase. A kinetic study with both cell-associated and isolated receptor
16. A urokinase-sensitive region of the human urokinase receptor is responsible for its chemotactic activity
17. Urokinase- and tissue-type plasminogen activators in keratinocytes during wound reepithelialization in vivo
18. Glycogen metabolism in psoriatic epidermis and in regenerating epidermis
19. Plasminogen activator in cultured human epidermal cells
20. Urokinase plasminogen activator cleaves its cell surface receptor releasing the ligand-binding domain
21. Single-chain urokinase-type plasminogen activator does not possess measurable intrinsic amidolytic or plasminogen activator activities
22. Plasminogen is present in the basal layer of the epidermis
23. Urokinase is a positive regulator of epidermal proliferation in vivo
24. Tissue plasminogen activator in psoriasis
25. Proteolytic processing of the 72,000-Da type IV collagenase by urokinase plasminogen activator
26. Effects of membrane-associated cathepsin B on the activation of receptor-bound prourokinase and subsequent invasion of reconstituted basement membranes
27. Detection of mRNA in tissue sections using Dig-labelled RNA and oligonucleotide probes
28. Keratins (K16 and K17) as markers of keratinocyte hyperproliferation in psoriasis in vivo and in vitro
29. Regulation of gelatinase activity in mice with targeted inactivation of components of the plasminogen/plasmin system
30. Gelatinase B-deficient mice are resistant to experimental bullous pemphigoid
31. Mechanism of activation of latent recombinant transforming growth factor β1 by plasmin
32. Control of type IV collagenase activity by components of the urokinase-plasmin system: A regulatory mechanism with cell-bound reactants
33. The wound repair-associated keratins 6, 16 and 17. Insights into the role of intermediate filaments in specifying keratinocyte cytoarchitecture
34. Urokinase receptor antagonists inhibit angiogenesis and primary tumor growth in syngeneic mice
35. Migrating keratinocytes express urokinase-type plasminogen activator
36. Extracellular proteolytic cleavage by urokinase is required for activation of hepatocyte growth factor/scatter factor
37. Demonstration of 72-kDa and 92-kDa forms of type IV collagenase in human skin: Variable expression in various blistering diseases, induction during re-epithelialization and decrease by topical glucocorticoids
38. Quantitative reverse zymography: Analysis of picogram amounts of metalloproteinase inhibitors using gelatinase A and B reverse zymograms
39. Correlation of proteolytic activities of organ cultured intact mouse skin with defined hair cycle stages
40. Transforming growth factor-β receptor type I and type II expression during murine hair follicle development and cycling
41. The plasminogen system and cell surfaces: Evidence for plasminogen and urokinase receptors on the same cell type
42. Limited cleavage of cellular fibronectin by plasminogen activator purified from transformed cells
43. Sequences 5' of the bovine keratin 5 gene direct tissue- and cell-type-specific expression of a lacZ gene in the adult and during development
44. Binding and activation of plasminogen at the surface of human keratinocytes
45. Lysine 156 promotes the anomalous proenzyme activity of tPA: X-ray crystal structure of single-chain human tPA
46. Proteolytic cleavage of the urokinase receptor substitutes for the agonist-induced chemotactic effect
47. The receptor for urokinase-type plasminogen activator is expressed by keratinocytes at the leading edge during reepithelialization of mouse skin wounds
48. Interstitial collagenase is expressed by keratinocytes that are actively involved in reepithelialization in blistering skin disease
49. Differential protease expression by cutaneous squamous and basal cell carcinomas
50. Novel regulation of type IV collagenase (matrix metalloproteinase-9 and -2) activities by transforming growth factor-β1 in human prostate cancer cell lines
51. Pemphigus IgG induces expression of urokinase plasminogen activator receptor on the cell surface of cultured keratinocytes
52. Inhibition of skin development by overexpression of transforming growth factor β1 in the epidermis of transgenic mice
53. A cleaved form of the receptor for urokinase-type plasminogen activator in invasive transplanted human and murine tumors
54. Concomitant secretion of prourokinase and of a plasminogen activator-specific inhibitor by cultured human monocytes-macrophages
55. A cellular binding site for the M(r) 55,000 form of the human plasminogen activator, urokinase
56. The plasminogen activator/plasmin system
57. Urokinase-catalyzed plasminogen activation at the monocyte/macrophage cell surface: A localized and regulated proteolytic system
58. ECM and cell surface proteolysis: Regulating cellular ecology
59. Urokinase-type plasminogen activator binding to its receptor stimulates tumor cell migration by enhancing integrin-mediated signal transduction
60. The receptor for urokinase-type plasminogen activator is expressed during mouse spermatogenesis
61. Extracellular proteolysis alters tooth development in transgenic mice expressing urokinase-type plasminogen activator in the enamel organ